期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

独辟蹊径的新型降糖药物——钠-葡萄糖共转运体抑制剂 被引量：1

SGLT2 inhibitors-latest archetype of antidiabetic drugs
下载PDF
导出
摘要 钠-葡萄糖协同转运蛋白-2是不依赖胰岛素方式,通过肾小管重吸收作用降低血糖的新型降糖药物。本文对此类药物的药代动力学及安全性、有效性等作了系统评估与综述。
作者 王福银 贾佩 李昌祁
机构地区 大庆龙南医院
出处 《药品评价》 CAS 2014年第19期27-29,38,共4页 Drug Evaluation
关键词 钠-葡萄糖协同转运蛋白-2 肾小管 重吸收
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献15

  • 1郭启煜.肾脏在血糖调节中的重要作用[J].药品评价,2014,11(9):27-30. 被引量：2
  • 2刘锴,宋海燕.钠-葡萄糖协同转运蛋白2抑制剂治疗糖尿病研究新进展[J].中国糖尿病杂志,2014,22(3):280-282. 被引量：5
  • 3Davis SN. Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin(CANTATA-SU trial)[J]. Expert Rev Clin Pharmacol, 2014, 7(I): 21-23.
  • 4Ridderstrale M, Svaerd R, Zeller C, et al. Rationale, design and baseline characteristics of a 4-year(208-week)phase 111 trial of empagliflozin, an SGLT-2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mcllitus with insufficient glycemic control[J]. Cardiovasc Diabetol, 2013, 12: 129.
  • 5Scheen AJ. Evaluating SGLT-2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations[J]. Expert Opin Drug Metab Toxicol, 2014, 10(5): 647-663.
  • 6Doggrell SA, Mclntyre K. Canagliflozin-something new for type 2 diabetes, but is it safe and efficacious[J]? Expert Opin Pharmacother, 2014, 15(3): 437-441.
  • 7Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase 111 studies of canagliflozin, a sodium glucose co- transporter 2 inhibitor[J]. Postgrad Med, 2014, 126(1): 7-17.
  • 8Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-transporter 2(SGLT-2)inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study[J]. Curt Med Res Opin, 2012, 28(7): 1167-1171.
  • 9Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies[J]. BMC Endocr Disord, 2014, 14: 37.
  • 10Lavalle-Gonzalez F J, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial[J]. Diabetologia, 2013, 56(12): 2582-2592.

二级参考文献30

  • 1Wright EM, Loo DD, Hirayama BA. Biology of human sodiumglucose transporters. Physiol Rev, 2011,91: 733-794.
  • 2Hummel CS, Lu C, Loo DD, et al. Glucose transport by hu-man renal Na+ /D- glucose cotransporters SGLT1 andSGLT2. Am J Physiol Cell Physiol, 2011, 300:C14-C21.
  • 3Lee YJ, Kim MO, Ryu JM, et al. Regulation of SGLT expres-sion and localization through Epac/PKA-dependent caveolin-1and F-actin activation in renal proximal tubule cells. BiochimBiophys Acta, 2012, 1823:971-982.
  • 4Nair S,Wilding JP. Sodium glucose cotransporter 2 inhibitorsas a new treatment for diabetes mellitus. J Clin EndocrinolMetab, 2010,95:34-42.
  • 5Maurer TS,Ghosh A, Haddish-Berhane N, et al. Pharmaco-dynamic model of sodium-glucose transporter 2(SGLT2) inhibi-tion: implications for quantitative translational pharmacology.AAPSJ, 2011,13:576-584.
  • 6Raskin P. Sodium-glucose cotransporter inhibition: therapeuticpotential for the treatment of type 2 diabetes mellitus. EHabetesMetab Res Rev, 2013,29:347-356.
  • 7Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, aselective SGLT2 inhibitor. improves ^ycemic control in streptozo-tocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol,2009, 609:148-154.
  • 8Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozineta-bonate, in a novel category of selective low-affinity sodium glu-cose cotransporter (SGLT2) inhibitors, exhibits antidiabeticefficacy in rodent models. J Pharmacol Exp Ther,2008, 327:268-276.
  • 9Grempler R,Thomas L,Eckhardt M, et al. Empagliflozin, anovel selective sodium glucosecotransporter-2 (SGLT-2) inhibi-tor: characterizationand comparison with other SGLT-2 inhibi-tors. Diabetes Obes Metab, 2012,14:83-90.
  • 10Luippold G,Klein T,Mark M,et al. Empagliflozin, a novelpotent and selective SGLT-2 inhibitor, improves glycaemic con-trol alone and in combination with insulin in streptozotocin-in-duced diabetic rats,a model of type 1 diabetes mellitus. Diabe-tes Obes Metab, 2012, 14:601-607.

共引文献5

同被引文献7

引证文献1

药品评价
2014年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部